The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically informed treatment across their geographic region.
The NHS South East Genomic Medicine Service has transitioned their large 500+ DNA gene panel Next Generation Sequencing (NGS) testing to OncoDEEP, which is a comprehensive genomic profiling kit supplied by OncoDNA.
“We have recently switched our large panel testing for small nucleotide variants (SNVs) and copy number variations (CNVs) to a new Solid Tumour Panel called OncoDEEP. The, OncoDEEP panel covers 638 genes, and also includes Homologous Recombination Deficiency (HRD) and microsatellite instability (MSI) testing in line with current Cancer National Genomic Test Directory requirements.
This change means:
- A streamlined service for DNA analysis of solid tumours with HRD testing included in the same panel.
- The panel has the capability to improve detection of copy number variants (CNVs), in particular copy number losses, and can deliver microsatellite instability (MSI) and tumour mutational burden (TMB) in a single assay.
- Sample preparation time is reduced enabling a more efficient work-flow, which supports a reduction in turnaround times in the longer term.
- This investment demonstrates our continued appetite to improve and transform our services underpinning our commitment to patients and clinicians.”
Nicola Foot, Head of Service and Clinical Scientist. South East Genomic Medicine Service
“We are delighted that the SE Genomic Medicine Service has transitioned to using the OncoDEEP Kit for the benefit of this patient population. We have become a key partner working closely to drive improvements from the ‘wet lab’ through to reporting’ supporting transformation of the entire workflow’. The successful introduction of the OncoDEEP Kit is evidence that our multidisciplinary approach where the different experts from OncoDNA all work closely with the different Genomic teams is what is needed to accompany our customers towards confidently using our solution in a routine setting. We look forward to continuing our work together to optimise the use of the OncoDEEP Kit and developing special projects to further evidence the benefits of targeted cancer treatments.”
Koenraad Eycken, Chief Product Officer at OncoDNA
About OncoDNA
Founded in 2012 with the vision of providing precision medicine in Oncology to multiple markets around the world, primarily focused on the patient. In a short space of time, we have made a significant contribution to the adoption of precision oncology as a result of providing a relevant solution to a wide range of customers, the core of which is our constantly updated database (OncoKDO).
Our scientific teams continuously scan the literature for new information in Oncology so we can develop tests that guide oncological treatments. Once we identify relevant biomarkers, we create accompanying tests (OncoDEEP, OncoSELECT). to detect and report on these biomarkers. The resulting reports are then shared through our user-friendly web-based platform (OncoKDM).
Our domain experience is evident, as we have reached the 7th iteration of our Comprehensive Genomic Profiling (CGP) OncoDEEP test, (which includes HRD) designed for solid tumour analysis. Additionally, we have developed various tests in liquid biopsies, catering to treatment selection (OncoSELECT).
In late 2022, we introduced the OncoDEEP kit, facilitating the transfer of our expertise to laboratories and hospitals so that our customers can perform in-house analyses using our reagents. This adaptation necessitated addressing several challenges, including establishing a robust logistical process, ensuring accessibility of Bio IT from different locations for data uploads, managing data from multiple sources, providing on-site training, and building a dedicated support function to meet the needs of our customers.
OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and accredited laboratories.
We are keen to meet laboratory partners and oncologists who would like to benefit from our expertise and work in partnership with us for the benefit of oncologists and their patients. For further information, visit www.oncodna.com and connect with us on LinkedIn.
MEDIA CONTACTS
KOENRAAD EYCKEN, Chief Product Officer, OncoDNA (+32 488 07 48 01)
